scholarly article | Q13442814 |
P50 | author | Dennis E. Hruby | Q113288408 |
P2093 | author name string | Chelsea M Byrd | |
Robert Rothlein | |||
Robert C Andrews | |||
Adnan M Mjalli | |||
Mohan Rao | |||
Tové C Bolken | |||
Katrina L Owens | |||
Murty N Arimilli | |||
Tariq Andrea | |||
P2860 | cites work | A low-viscosity epoxy resin embedding medium for electron microscopy | Q26778471 |
A new protease required for cell-cycle progression in yeast | Q27938681 | ||
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus | Q29614207 | ||
Vaccinia Virus Replication I. Requirement for the Host-Cell Nucleus | Q30850654 | ||
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir | Q33545117 | ||
Cidofovir in the treatment of poxvirus infections | Q34134474 | ||
In vitro activity of potential anti-poxvirus agents | Q35077243 | ||
Smallpox vaccination: a review, part II. Adverse events | Q35175732 | ||
Encephalitis complicating smallpox vaccination | Q35182272 | ||
Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the I7 gene that encodes a virion component | Q36645421 | ||
The vaccinia virus I7L gene product is the core protein proteinase | Q39686660 | ||
Molecular Dissection of the Vaccinia Virus I7L Core Protein Proteinase | Q39997670 | ||
African swine fever virus protease, a new viral member of the SUMO-1-specific protease family | Q40613575 | ||
Sensitivity of herpes simplex virus, vaccinia virus, and adenoviruses to deoxyribonucleic acid inhibitors and thiosemicarbazones in a plaque suppression test | Q41019711 | ||
A SIMPLIFIED LEAD CITRATE STAIN FOR USE IN ELECTRON MICROSCOPY. | Q41066255 | ||
Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis | Q41372087 | ||
Rifampicin: a specific inhibitor of vaccinia virus assembly | Q43498675 | ||
Selective inhibition of vaccinia virus by the antibiotic rifampicin | Q44293072 | ||
Relation of poly(adenosine diphosphoribose) synthesis to DNA synthesis and cell growth | Q44438710 | ||
Immunolocalization of vaccinia virus structural proteins during virion formation | Q45776741 | ||
Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus | Q45795296 | ||
Specific inhibition of vaccinia virus growth by 2'-O-methyladenosine: isolation of a drug-resistant virus mutant | Q45795835 | ||
The effect of hydroxyurea on virus development. II. Vaccinia virus | Q45812224 | ||
An abbreviated method of the double lead stain technique | Q68958412 | ||
Selection of recombinant vaccinia viruses on the basis of plaque formation | Q71866680 | ||
P433 | issue | 22 | |
P304 | page(s) | 12147-12156 | |
P577 | publication date | 2004-11-01 | |
P1433 | published in | Journal of Virology | Q1251128 |
P1476 | title | New class of orthopoxvirus antiviral drugs that block viral maturation | |
P478 | volume | 78 |
Q34676027 | 5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity |
Q36505563 | A novel inhibitor of dengue virus replication that targets the capsid protein |
Q34421628 | Activity, specificity, and probe design for the smallpox virus protease K7L |
Q35039792 | Analysis of vaccinia virus temperature-sensitive I7L mutants reveals two potential functional domains |
Q35784850 | Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors |
Q27652695 | Crystal structure of poxvirus thymidylate kinase: An unexpected dimerization has implications for antiviral therapy |
Q24811081 | Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity |
Q33303858 | Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches |
Q38617932 | Historical perspectives in the development of antiviral agents against poxviruses |
Q33302240 | Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly |
Q42143723 | Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide |
Q33234918 | Mutational analysis of the potential catalytic residues of the VV G1L metalloproteinase |
Q34583461 | Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase |
Q36074391 | Orthopoxvirus targets for the development of antiviral therapies |
Q37173398 | Orthopoxvirus targets for the development of new antiviral agents. |
Q42122542 | Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication |
Q42974816 | Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system |
Q35759004 | Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase |
Q34698954 | Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues |
Q38089868 | The design and development of drugs acting against the smallpox virus. |
Q34984243 | Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure |
Q40195477 | Vaccinia virus G1 protein: absence of autocatalytic self-processing. |
Q36482612 | Vaccinia virus proteolysis--a review |